Adrenal function under long-term raloxifene administration

Gynecological Endocrinology

Volumn 17, Issue 2, 2003, Pages 159-168

  Genazzani, A R ^a   Lombardi, I ^a   Borgioli, G ^a   Di Bono, I ^a   Casarosa, E ^a   Gambacciani, M ^a   Palumbo, M ^b   Genazzani, A D ^c   Luisi, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

ACTH; Adrenal Steroids; CRF; Raloxifene

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANDROGEN; ANDROSTENEDIONE; BETA ENDORPHIN; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; ESTRADIOL; ESTRONE; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYPROGESTERONE; PRASTERONE; PRASTERONE SULFATE; PROGESTERONE; PROGESTERONE DERIVATIVE; RALOXIFENE;

ADRENAL CORTEX; ADRENAL FUNCTION; ADULT; ANDROGEN BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER PREVENTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENDOMETRIUM CARCINOMA; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HORMONAL REGULATION; HORMONE ACTION; HORMONE SENSITIVITY; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROPROTECTION; NEUROTOXICITY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; STEROID BLOOD LEVEL; STEROIDOGENESIS;

EID: 0037394028     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.17.2.159.168     Document Type: Article

References (33)

1. Jensen EV. Steroid hormones, receptors and antagonists. Ann NY Acad Sci 1996;784:1-17
2. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonist and antagonist in the estrogen receptor. Nature (London) 1997;389:753-8
3. Bryant HU, Glasebrook AL, Yang NN, et al. A pharmacological review of raloxifene. J Bone Miner Metab 1996;14:1-9
4. Delmas PD, Bjarnasn NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
5. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64
6. Dickler MN, Norton L. The MORE trial: multiple outcomes for raloxifene evaluation - breast cancer as a secondary end point: implications for prevention. Ann NY Acad Sci 2001;949:134-42
7. Grodishar WJ. The effect of raloxifene on the risk of breast cancer in post menopausal women. 20th American San Antonio Breast Cancer Symposium, San Antonio, Texas, December 1997
8. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Am J Metab Acad 1999;281:2189-97
9. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Am J Metab Acad 1998;279:1445-51
10. Simoncini T, Genazzani AR. Direct vascular effects of estrogens and selective estrogen receptor modulators. Curr Opin Obstet Gynecol 2000;12:181-7
11. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966-9
12. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002;105:1368-73
13. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:1512-19
14. Zhou W, Koldzic-Zivanovic N, Clarke CH, et al. Selective estrogen receptor modulator effects in rat brain. Neuroendocrinology 2002;75:24-33
15. Genazzani AR, Bernardi F, Stomati M, et al. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovari-ectomized rats. Neuroendocrinology 2000;72:162-70
16. Nilsen J, Naftolin F. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 1998;5:211-16
17. Stomati M, Bersi C, Rubino S, et al. Neuroendocrine effects of different estradiol-progestin regimens in postmenopausal women. Maturitas 1997;28:127-35
18. Neele SJ, Evertz R, Genazzani AR, et al. Raloxifene treatment increases plasma levels of β-endorphin in postmenopausal women: a randomized, placebo-controled study. Fertil Steril 2002;77:1110-17
19. Florio P, Quirici B, Casarosa E, et al. Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women. Gynecol Endocrinol 2001;15:359-66
20. Labrie F, Belanger A, Cusan L, et al. Marked decline in serum concentration of adrenal C-19 sex steroid precursors and conjugated androgen metabolites dunng ageing. J Clin Endocrinol Metab 1997;82:2396-402
21. Akamatsu T, Chiba H, Kamiyama H, et al. Menopause related changes of adrenocortical steroid production. Asia Oceania J Obstet Gynaecol 1992;18:271-6
22. Genazzani AR, Petraglia F, Bernardi F, et al. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J Clin Endocrinol Metab 1998;83:2099-103
23. Chowen JA, Argente J, Vician L, et al. Pro-opiomelanocortin messenger RNA in hypothalamic neurons is increased by testosterone through aromatization to estradiol. Neuroendocrinology 1990;52:581-8
24. Cheung S, Hammer RP. Gonadal steroids hormone regulation of pro-opiomelanocortin gene expression in arcuate neurons that innervate the medial preoptic area of the rat. Neuroendocrinology 1995;62:283-92
25. Albrencht ED, Pepe GJ. Effect of estrogen on dehydroepiandrosterone formation by baboon fetal adrenal cells in vitro. Am J Obstet Gynecol 1987;156:1275-8
26. Hirst JJ, West NB, Brenner RM, et al. Steroid hormone receptors in the adrenal glands of fetal and adult rhesus monkeys. J Clin Endocrinol Metab 1992;75:3078-84
27. Casson PR, Elkind-Hirsch KE, Buster JE, et al. Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 1997;90:995-8
28. Simon J, Klaiber E, Wiita B, et al. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999;6:138-46
29. Kraemer RR, Synovitz LB, Gimpel T, et al. Effect of estrogen on serum DHEA in younger and older women and the relationship of DHEA to adiposity and gender. Metabolism 2001;50:488-93
30. Lobo RA, Gobelsmann U, Brenner PF, et al. The effect of estrogen on adrenal androgens in oopho-rectomized women. Am J Obstet Gynecol 1982;142:471-8
31. Fonseca E, Basurto L, Velasquez S, et al. Hormone replacement therapy increases ACTH/DHEA-S in postmenopause. Maturitas 2001;39:57-62
32. Bernardi F, Pieri M, Stomati M, et al. Circulating allopregnanolone and DHEA levels in postmenopausal women under various hormonal replacement therapies. Gynecol Endocrinol 2003;17:65-78
33. Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with high risk of breast cancer. Ann Intern Med 1999;130:270-7